Inventiva (IVA) News Today $3.35 -0.03 (-0.89%) Closing price 07/11/2025 03:55 PM EasternExtended Trading$3.36 +0.01 (+0.27%) As of 07/11/2025 04:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock IVA Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 Time Period Inventiva appoints new R&D president and regulatory affairs executiveJuly 11 at 9:00 AM | investing.comInventiva names Jason Campagna as President of R&D and Chief Medical ...July 11 at 9:00 AM | finance.yahoo.comInventiva Strengthens Leadership Team Ahead of Key MASH Drug MilestonesJuly 10 at 3:08 PM | yahoo.comInventiva names Jason Campagna as President of R&D and Chief Medical Officer and Martine Zimmermann as Executive Vice President of Regulatory Affairs and Quality AssuranceJuly 9 at 4:17 PM | globenewswire.comINVENTIVA: Inventiva receives $10 million milestone payment from CTTQJuly 8, 2025 | finanznachrichten.deInventiva receives $10 million milestone payment from CTTQJuly 7, 2025 | globenewswire.comInventiva (NASDAQ:IVA) Trading 2.7% Higher - Here's WhyJuly 4, 2025 | marketbeat.comInventiva announces the publication in Journal of Hepatology Reports on results of lanifibranor treatment on liver sinusoidal endothelial cells in patients with MASLD/MASH and in preclinical models of the diseaseJuly 2, 2025 | globenewswire.comInventiva S.A. (IVA) Latest Stock News & Headlines - Yahoo FinanceJune 24, 2025 | finance.yahoo.comCanaccord Genuity Maintains a Buy on Inventiva (IVA) With a $20 Price TargetJune 24, 2025 | msn.comInventiva appoints former Calliditas CEO to board of directorsJune 11, 2025 | uk.investing.comInventiva (NASDAQ:IVA) Stock Price Up 0.8% - Here's WhyJune 11, 2025 | marketbeat.comINVENTIVA: Inventiva Announces the Appointment of Renée Aguiar-Lucander to its Board of DirectorsJune 11, 2025 | finanznachrichten.deInventiva S.A. (NASDAQ:IVA) Short Interest Down 12.1% in MayJune 4, 2025 | marketbeat.comINVENTIVA: Inventiva to Participate in the Upcoming Jefferies Global Healthcare Conference and UBS Spring Biotech ConferenceMay 27, 2025 | finanznachrichten.deInventiva to Participate in the Upcoming Jefferies Global Healthcare Conference and UBS Spring Biotech ConferenceMay 27, 2025 | globenewswire.comInventiva S.A. reports Q1 resultsMay 23, 2025 | seekingalpha.comINVENTIVA: Inventiva reports 2025 First Quarter Financial InformationMay 23, 2025 | finanznachrichten.deInventiva reports 2025 First Quarter Financial Information¹May 23, 2025 | globenewswire.comResults of the Votes of the Combined Shareholders' General Meeting of May 22, 2025May 23, 2025 | globenewswire.comDescription of the Share Repurchase Program Covered by the Liquidity Agreement with Kepler ChevreuxMay 22, 2025 | uk.finance.yahoo.comInventiva (NASDAQ:IVA) Trading Up 1.3% - Here's WhyMay 22, 2025 | marketbeat.comINVENTIVA: Inventiva secures the €116 million second tranche of its structured financing of up to €348 millionMay 6, 2025 | finanznachrichten.deInventiva Secures €115.6 Million Through T2 Subscription AgreementMay 5, 2025 | tipranks.comInventiva secures €116 million second tranche of structured financing of up to €348 millionMay 5, 2025 | msn.comInventiva secures the €116 million second tranche of its structured financing of up to €348 millionMay 5, 2025 | globenewswire.comCombined General Meeting of May 22, 2025 - Availability of the preparatory documentsApril 30, 2025 | globenewswire.comInventiva (NASDAQ:IVA) Shares Up 3.2% - Time to Buy?April 28, 2025 | marketbeat.comInventiva announces the publication in Clinical Gastroenterology and Hepatology of its analysis of new biomarker signatures predictive of histological response in patients with MASH treated with lanifibranorApril 24, 2025 | globenewswire.comINVENTIVA: Inventiva announces filing of its 2024 Universal Registration Document and 2024 Annual Report on Form 20-FApril 15, 2025 | finanznachrichten.deInventiva announces filing of its 2024 Universal Registration Document and 2024 Annual Report on Form 20-FApril 15, 2025 | globenewswire.comInventiva S.A. (NASDAQ:IVA) Given Consensus Recommendation of "Moderate Buy" by BrokeragesApril 6, 2025 | marketbeat.comGuggenheim Issues Pessimistic Forecast for Inventiva (NASDAQ:IVA) Stock PriceApril 6, 2025 | marketbeat.comInventiva price target lowered to $9 from $12 at GuggenheimApril 5, 2025 | markets.businessinsider.comInventiva achieves milestone with Phase 3 study enrollment, says H.C. WainwrightApril 3, 2025 | markets.businessinsider.comInventiva stock rises following NATiV3 trial enrollment completionApril 2, 2025 | investing.comInventiva announces completion of enrollment in the Phase 3 NATiV3 clinical trial of lanifibranor in patients with MASH and advanced fibrosisApril 1, 2025 | globenewswire.comHC Wainwright Reaffirms "Buy" Rating for Inventiva (NASDAQ:IVA)March 29, 2025 | marketbeat.comInventiva S.A. (IVA) Q4 2024 Earnings Call TranscriptMarch 27, 2025 | seekingalpha.comINVENTIVA: Inventiva reports its 2024 full year results and provides a business updateMarch 26, 2025 | finanznachrichten.deInventiva reports its 2024 full year results and provides a business updateMarch 26, 2025 | globenewswire.comInventiva announces the schedule of publication and presentation of its 2024 Full-Year Financial ResultsMarch 19, 2025 | globenewswire.comInventiva (IVA) Expected to Announce Earnings on WednesdayMarch 19, 2025 | marketbeat.comInventiva (NASDAQ:IVA) Stock Price Down 0.7% - What's Next?March 15, 2025 | marketbeat.comInventiva publishes lanifibranor results in Biomedicine & PharmacotherapyFebruary 26, 2025 | markets.businessinsider.comInventiva announces the publication in Biomedicine & Pharmacotherapy of the results from a preclinical study showing improvement of portal hypertension with lanifibranor treatmentFebruary 26, 2025 | globenewswire.comInventiva (NASDAQ:IVA) Now Covered by Analysts at TD CowenFebruary 22, 2025 | marketbeat.comInventiva initiated with a Buy at TD CowenFebruary 21, 2025 | markets.businessinsider.comInventiva & Japan’s Hepalys start lanifibranor clinical development programFebruary 21, 2025 | markets.businessinsider.comInventiva and Hepalys Pharma, Inc. announce the initiation of the clinical development program of lanifibranor in Japan with the dosing of the first participant in Phase 1 trialFebruary 20, 2025 | globenewswire.com Get Inventiva News Delivered to You Automatically Sign up to receive the latest news and ratings for IVA and its competitors with MarketBeat's FREE daily newsletter. Email Address IVA Media Mentions By Week IVA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IVA News Sentiment▼0.281.00▲Average Medical News Sentiment IVA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IVA Articles This Week▼72▲IVA Articles Average Week Get Inventiva News Delivered to You Automatically Sign up to receive the latest news and ratings for IVA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies PAHC News Today ABCL News Today NTLA News Today AMPH News Today WVE News Today AUPH News Today ARDX News Today ELVN News Today VERV News Today NAGE News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:IVA) was last updated on 7/12/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inventiva S.A. Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Inventiva With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.